68 related articles for article (PubMed ID: 3298621)
1. Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
Smith EF; Egan JW
J Pharmacol Exp Ther; 1987 Jun; 241(3):855-60. PubMed ID: 3298621
[TBL] [Abstract][Full Text] [Related]
2. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
[TBL] [Abstract][Full Text] [Related]
3. Synergism between a phosphodiesterase inhibitor and modulators of thromboxane formation on thrombin-induced sudden death in rabbits.
Smith EF; Olson RW
Prog Clin Biol Res; 1987; 242():241-6. PubMed ID: 3671385
[No Abstract] [Full Text] [Related]
4. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
[TBL] [Abstract][Full Text] [Related]
5. In vivo interaction of prostacyclin with an inhibitor of cyclic nucleotide phosphodiesterase, HL 725.
Darius H; Lefer AM; Leprán I; Smith JB
Br J Pharmacol; 1985 Mar; 84(3):735-41. PubMed ID: 2985163
[TBL] [Abstract][Full Text] [Related]
6. CGS 15435A, a thromboxane synthetase inhibitor with an extended duration of action: a comparison with dazoxiben.
Olson RW; Cohen DS; Ku EC; Kimble EF; Renfroe HB; Smith EF
Eur J Pharmacol; 1987 Jan; 133(3):265-73. PubMed ID: 3104066
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
Bitterman H; Phillips GR; Dragon G; Lefer AM
J Pharmacol Exp Ther; 1987 Jul; 242(1):8-14. PubMed ID: 3039116
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis.
Romson JL; Hook BG; Lucchesi BR
J Pharmacol Exp Ther; 1983 Nov; 227(2):288-94. PubMed ID: 6313894
[TBL] [Abstract][Full Text] [Related]
9. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
[TBL] [Abstract][Full Text] [Related]
10. Modulation of vascular thrombosis by products of arachidonic acid metabolism.
Wu KK; Hall ER; Papp A
Clin Physiol Biochem; 1984; 2(2-3):84-90. PubMed ID: 6435930
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
12. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats.
Pawlak R; Chabielska E; Golatowski J; Azzadin A; Buczko W
Thromb Haemost; 1998 Jun; 79(6):1208-12. PubMed ID: 9657449
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the thromboxane synthetase inhibitor dazoxiben and the prostacyclin mimetic iloprost in an animal model of acute ischaemia and reperfusion.
Thiemermann C; Schrör K
Biomed Biochim Acta; 1984; 43(8-9):S151-4. PubMed ID: 6083783
[TBL] [Abstract][Full Text] [Related]
14. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
[TBL] [Abstract][Full Text] [Related]
15. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Shebuski RJ; Storer BL; Fujita T
Thromb Res; 1988 Dec; 52(5):381-92. PubMed ID: 3146820
[TBL] [Abstract][Full Text] [Related]
16. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
[TBL] [Abstract][Full Text] [Related]
17. Pneumotoxicity of lipopolysaccharide in nitric oxide-deficient rats is limited by a thromboxane synthase inhibitor.
Wołkow PP; Bartuś JB; Gryglewski RJ
J Physiol Pharmacol; 1997 Dec; 48(4):645-53. PubMed ID: 9444613
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion.
Menys VC; Davies JA
Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological, hematological, and physiological effects of a new thromboxane synthetase inhibitor (CGS-13080) during cardiopulmonary bypass in dogs.
DeCampli WM; Goodwin D; Kosek JC; Handen CE; Mitchell RS; Miller DC
Ann Thorac Surg; 1986 Dec; 42(6):690-6. PubMed ID: 3789860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
